🔗 Share this article Patients Stopping Anti-Obesity Injections Gain Back Weight at a Quadrupled Rate Than Dieters Weight management involves long-term strategies. Fresh analysis reveals that individuals who stop using new slimming jabs like Mounjaro or Wegovy tend to recover reduced body mass much more quickly than those who halt conventional lifestyle programs. Research printed in a major medical journal shows that while obese people often shed a large proportion of their total mass while undergoing treatment, the weight comes back at an average rate of nearly a kilo each month once they quit. "Individuals using these medications should be cognizant of the risk of rapid weight regain when the therapy is stopped," warns expert Dr. Susan Jebb. This pace of regain implies a return to original weight in about 18 months. Comparing Treatments The study, which examined dozens of trials involving thousands of participants, compared the results of GLP-1 agonists with older methods. Scientists emphasize that individuals who shed pounds through diet and exercise usually have a less rapid weight regain—perhaps 100 grams monthly—after stopping. Explaining the Rapid Rebound Doctors propose the mechanism of the injections explains the heightened regain. GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which moderates hunger. "Artificially providing the hormone levels several times higher than normal could lead to the system to generate a reduced amount of its endogenous GLP-1, and could lessen responsiveness to its actions," said Dr. Adam Collins, a nutrition researcher. "Discontinuation of this GLP-1 'fix' results in appetite is no longer kept in check, making overeating a significant risk." A Chronic Disease? The NHS advise the jabs for people with weight-linked health risks, alongside prescribed lifestyle changes. Many experts argue that, due to the high risk of relapse, the treatment is often life-long. This perspective is supported by drug manufacturers, who say that the findings "highlight the persistent character of obesity," comparing it to managing conditions like high blood pressure. User Experiences Individuals who have discontinued the jabs explain a intense resurgence of hunger. "It felt as if a switch that goes on and you're instantly ravenous," recalled an individual. The struggle is compounded if users have not adopted permanent dietary or behavioural modifications during therapy. Widespread Adoption Figures indicate that a significant number of adults in the UK have tried these injections in the last 12 months, with desire being substantial. Adoption is higher among women compared to men. The middle-aged age group shows the greatest usage rates. A large proportion access the drugs through private healthcare rather than public health services. Ultimately, researchers caution that while GLP-1 drugs are effective tools for weight loss, they are not a standalone cure and long-term success relies on combined behavioural management.
Weight management involves long-term strategies. Fresh analysis reveals that individuals who stop using new slimming jabs like Mounjaro or Wegovy tend to recover reduced body mass much more quickly than those who halt conventional lifestyle programs. Research printed in a major medical journal shows that while obese people often shed a large proportion of their total mass while undergoing treatment, the weight comes back at an average rate of nearly a kilo each month once they quit. "Individuals using these medications should be cognizant of the risk of rapid weight regain when the therapy is stopped," warns expert Dr. Susan Jebb. This pace of regain implies a return to original weight in about 18 months. Comparing Treatments The study, which examined dozens of trials involving thousands of participants, compared the results of GLP-1 agonists with older methods. Scientists emphasize that individuals who shed pounds through diet and exercise usually have a less rapid weight regain—perhaps 100 grams monthly—after stopping. Explaining the Rapid Rebound Doctors propose the mechanism of the injections explains the heightened regain. GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which moderates hunger. "Artificially providing the hormone levels several times higher than normal could lead to the system to generate a reduced amount of its endogenous GLP-1, and could lessen responsiveness to its actions," said Dr. Adam Collins, a nutrition researcher. "Discontinuation of this GLP-1 'fix' results in appetite is no longer kept in check, making overeating a significant risk." A Chronic Disease? The NHS advise the jabs for people with weight-linked health risks, alongside prescribed lifestyle changes. Many experts argue that, due to the high risk of relapse, the treatment is often life-long. This perspective is supported by drug manufacturers, who say that the findings "highlight the persistent character of obesity," comparing it to managing conditions like high blood pressure. User Experiences Individuals who have discontinued the jabs explain a intense resurgence of hunger. "It felt as if a switch that goes on and you're instantly ravenous," recalled an individual. The struggle is compounded if users have not adopted permanent dietary or behavioural modifications during therapy. Widespread Adoption Figures indicate that a significant number of adults in the UK have tried these injections in the last 12 months, with desire being substantial. Adoption is higher among women compared to men. The middle-aged age group shows the greatest usage rates. A large proportion access the drugs through private healthcare rather than public health services. Ultimately, researchers caution that while GLP-1 drugs are effective tools for weight loss, they are not a standalone cure and long-term success relies on combined behavioural management.